10 Best Long Term Stocks to Buy According to Hedge Funds
Allan Small of Allan Small Financial Group told BNN Bloomberg that the S&P 500 is near all-time highs but leadership is uneven, with semiconductors stronger while some Mag 7 names have sold off. He expects periodic pullbacks (historically 5%-10% a few times yearly) and urged diversification. The article lists hedge-fund favored long-term stocks, including Medtronic (FDA 510(k) clearance for Nellcor Nell-EQ) and Lowe’s (AI “Material Lists” for Pro quoting).
How this was made
The 30-second read
Why it matters
The only concrete, company-specific catalysts provided are (1) Medtronic’s FDA 510(k) clearance for a new pulse oximetry system and (2) Lowe’s launch of an AI tool for Pro quoting workflows; neither includes financial guidance or quantified outcomes.
Market read
Traders get incremental product/regulatory detail for MDT and a retail digitization update for LOW, but the article is not a fresh earnings/guidance/price-action catalyst.
What to watch
For MDT, investors will still need reimbursement/competitive adoption data; for LOW, the key question is whether Material Lists meaningfully improves conversion rates or margins versus existing Pro tools.
Background
The piece is a hedge-fund “best long-term stocks” list, framed around market leadership and diversification, and then highlights two named companies with recent developments.
Ticker impact
Medtronic received FDA 510(k) clearance for its Nellcor Nell-EQ pulse oximetry system and plans global launch in coming months.
Modest upside bias around rollout expectations; magnitude likely limited without new financial guidance.
The article cites a specific regulatory clearance and launch timing, but provides no revenue/earnings impact or consensus estimates.
Lowe’s introduced an AI-powered “Material Lists” tool for Pro customers to digitize material inputs and generate quote-ready orders faster.
Limited near-term price impact; any effect would likely show up gradually in customer engagement metrics.
This is a feature/product launch with qualitative benefits and no disclosed traction, pricing, or guidance changes.
Market effects
Reinforces ongoing investment in healthcare device innovation (MDT) and retail digitization/AI enablement (LOW), but without broader sector data.
Primarily US-focused retail and US FDA regulatory context; limited direct regional spillover.
MDT’s “global” launch intent is the main international angle; LOW’s tool is positioned for US/Canada Pro workflows.
Counterpoint
These are promotional “best stocks” selections; the article provides no valuation, estimates, or quantified traction, so near-term trading signals may be overstated.
Key entities
- companyMedtronic
FDA 510(k) clearance for Nellcor Nell-EQ pulse oximetry system; global launch planned in coming months.
- companyLowe’s Companies
Introduced “Material Lists,” an AI-powered tool to digitize material inputs and generate quote-ready orders for Pro customers.
- personAllan Small Financial Group / Allan Small
BNN Bloomberg guest discussing market leadership and diversification; not a company-specific catalyst.
